Asia-Pacific COPD market is forecast to grow to over $6.5 billion in 2023
COPD Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies
LONDON, Jan. 3, 2018 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/4647444
Summary
Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of airflow that interferes with normal breathing. COPD occurs most often in older adults, but can also affect middle-aged people. It is not common in younger adults, as their lungs are still in a healthy state, and it takes several years for COPD to develop. There are two main forms of COPD: chronic bronchitis, which involves a long-term cough with mucus; and emphysema, which involves damage to the lungs over time.
Asia-Pacific (APAC) chronic obstructive pulmonary disease (COPD) market is forecast to grow from around $3.8 billion in 2016 to over $6.5 billion in 2023, at a compound annual growth rate (CAGR) of around 8.7%. Over the forecast period the prevalence of COPD is expected to increase significantly across the APAC markets, mainly due to an increase in the smoking population, as the disease is more common among smokers (Lim et al., 2015).
Existing COPD therapies are aimed at managing the frequency and severity of the symptoms, and none have been shown to modify long-term disease progression. Roflumilast, which is the only targeted therapy available in the COPD market, has significant anti-inflammatory effects. However, the dosing of roflumilast is limited due to its side effects, which means that the therapeutic benefit is marginal.
The report "COPD Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies" detailing the key points driving the COPD market in the five Asia-Pacific markets: India, China, Australia, South Korea and Japan.
In particular, this report provides the following
- Provides an introduction to COPD, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, disease staging and prognosis for patients. An analysis of current treatment algorithms and options are also included..
- Offers detailed analysis of the drugs currently marketed for COPD, detailing their key characteristics, including safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, pricing, and overall competitive strength.
- Provides detailed analysis of the pipeline for COPD, by stage of development, molecule type, program type, mechanism of action and molecular target.
- Provides detailed analysis of recent clinical trials in this indication by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
- Provides detailed analysis of key market drivers and barriers for the COPD market.
Scope
- The COPD Asia-Pacific market will be valued at $6.7 billion in 2023, growing from $3.8 billion in 2016 at a CAGR of 8.7%.
- Bronchodilators and ICS therapies dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs?
- Do branded therapies show continuous growth, and are they facing competition from generics?
- How will branded therapies be affected by upcoming pipeline therapies?
- The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.
- Which molecular targets appear most frequently in the pipeline?
- Will the pipeline address unmet needs related to limited targeted therapies for COPD patients?
- What first-in-class triple combinations are due to enter the COPD market within the forecast period, and how will they compete with the currently marketed products?
- Various drivers and barriers will influence the market over the forecast period.
- What barriers will limit the uptake of premium-priced therapeutics in the assessed countries?
- What factors are most likely to drive the market in these countries?
Reasons to buy
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the COPD market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the COPD pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict COPD market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals.
Download the full report: https://www.reportbuyer.com/product/4647444
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article